is janumet a glp 1 XR: Uses, Side Effects, Dosage & More Janumet and Janumet XR |

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026

One self-pay platform

A budget-first approach to expanding preventative weight health benefits without health plan shock.

Expert guidance on managing side effects, choosing nutrient-dense foods, and creating sustainable meal plans for optimal results with GLP-1 medications.